The continued consolidation in the pharmaceutical industry has baffled many individuals. Confronted with major threats like patent losses, a depressed economic environment, soaring R&D costs, low productive development pipelines, pricing pressure and generic competition, Big Pharma has struck multibillion dollar deals like the Pfizer - Wyeth acquisition in 2009. In this case, we contrast small biotech with Big Pharma.